Increase in claimed class-action damages points to larger settlements
Execs falsely inflated firm's revenues to enable acquisition, regulator charges
Ex-CEO misled investors over regulatory approval for new drugs
U.S. authorities allege biostatistician traded on cancer drug data
Regulator settled with Rio Tinto, former CEO in 2023
SEC, DoJ charge six in market manipulation, insider trading schemes
CFTC pays second award of 2025, SEC's payouts out of the spotlight
Accountant allegedly found assets used to lure investors to schemes
Execs that previously pleaded guilty in fraud case accept regulatory sanctions
Changes allow SRO to match SEC on standards for inter-listed stocks